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Abstract
Background: Latent tuberculosis infection (LTBI) control relies on high initiation and completion rates of preventive
treatment to preclude progression to tuberculosis disease. Specific interventions may improve initiation and completion
rates. The objective was to systematically review data on determinants of initiation, adherence and completion of LTBI
treatment, and on interventions to improve initiation and completion.
Methods: A systematic review of the literature (PubMed, Embase) published up to February 2014 was performed.
Relevant prospective intervention studies were assessed using GRADE.
Results: Sixty-two articles reporting on determinants of treatment initiation and completion were included and
23 articles on interventions. Determinants of LTBI treatment completion include shorter treatment regimen
and directly observed treatment (DOT, positive association), adverse events and alcohol use (negative association), and
specific populations with LTBI (both positive and negative associations). A positive effect on completion was noted in
intervention studies that used short regimens and social interventions; mixed results were found for intervention
studies that used DOT or incentives.
Conclusion: LTBI treatment completion can be improved by using shorter regimens and social interventions.
Specific needs of the different populations with LTBI should be addressed taking into consideration the setting
and condition in which the LTBI treatment programme is implemented.
Keywords: Tuberculosis, Latent tuberculosis, Treatment initiation, Treatment adherence, Treatment completion,
Risk groups
Background
Exposure to Mycobacterium tuberculosis may result in
latent tuberculosis infection (LTBI). LTBI can in turn
progress to tuberculosis (TB) disease, especially if the
immune system is compromised [1, 2]. One-third of the
world population is estimated to be latently infected
with M. tuberculosis [3]; therefore, LTBI control is an
important step towards TB elimination, in addition to
TB case detection and treatment [4, 5]. LTBI control
consists of identifying individuals with LTBI and offering
them preventive treatment. The fact that initiation and
completion rates of preventive treatment are often low
and differ between treatment regimens and populations
with LTBI may hamper the control of LTBI.
Numerous factors can influence patients’ medication
uptake, such as forgetfulness, side effects, stigma, or lack
of information on treatment requirements, thereby af-
fecting initiation, adherence and completion rates of
treatment. These factors affecting patients’ medication
uptake have to be considered when designing interven-
tions to modify complex human behaviour associated
with treatment adherence [6–8]. Specific examples of
interventions that have been used to improve initiation,
adherence, or completion of LTBI treatment include
switching from regimens with longer treatment duration
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to regimens with shorter treatment duration [9], incentives
[10], and education or counselling [7].
In order to provide European Union and European
Economic Area (EU/EEA) Members States and candidate
countries with guidance on programmatic LTBI control a
systematic review on initiation and completion of prevent-
ive treatment was performed in a bilateral cooperation
with the World Health Organization (WHO) [11]. The
review served as input for the WHO guidelines on
management of LTBI launched in 2015 [11], and will be
used for the EU/EEA tailored guidance. The review
questions were (1) What are the initiation and completion
rates of different LTBI treatment regimens?; (2) What are
the determinants of initiation, adherence, and completion
of recommended LTBI treatment regimens in the general
population and in specific populations with LTBI?; and (3)
What are interventions with demonstrated efficacy to
improve LTBI treatment initiation, adherence and com-
pletion in different populations?. The current article pre-
sents the results on the latter two review questions.
Methods
A systematic literature review was performed to pro-
vide answers to the review questions described above.
This review was done according to a review protocol
and following the Cochrane guidelines. The details of
eligibility criteria, information sources, search strategy,
study selection, and data extraction are provided in
the Additional files (see Additional file 1).
Data extraction
To answer review question 2, data on determinants of
initiation, adherence, and completion were extracted for
individuals with LTBI from various populations with
LTBI (e.g. p-values, odds ratios (ORs), risk ratios). If uni-
variate and multivariate analyses of the same data were
presented, only the data from the multivariate analysis
were extracted. Results from intention-to-treat analyses
were preferred; if both intention-to-treat and per-protocol
results were reported in one study, only intention-to-treat
results were included. Data on non-significant factors
were not consistently quantified in the studies and were
therefore not listed in this review.
For review question 3, data for five groups of interven-
tions were extracted: 1. interventions with short treatment
regimens; 2. interventions consisting of directly observed
therapy (DOT); 3. interventions in which incentives were
offered with the treatment (e.g. cash, transportation
vouchers); 4. social interventions (e.g. education, adher-
ence coaching, peer counselling, cultural interventions);
and 5. other interventions (e.g. use of interferon gamma
release assay (IGRAs) rather than tuberculin skin tests
(TSTs)). ORs that were adjusted for factors that related to
the intervention were not used.
GRADE
As review question 2 does not deal with the effects
of health interventions, risk of bias was only assessed
for aspects of the individual studies and not across
the evidence base. For review question 3, the quality
of the total body of evidence for each outcome (initi-
ation, adherence, and completion rates) was critically
appraised using the GRADE approach (Grading of
Recommendations Assessment, Development and Evalu-
ation; http://www.gradeworkinggroup.org). Only prospect-
ive studies (i.e. randomized controlled trials (RCTs) and
prospective observational studies) were appraised using
GRADE. Outcomes were downgraded for imprecision
when the total number of events was less than 125 for
dichotomous outcomes, and if the total sample size was
less than 230 for continuous outcomes (based on esti-
mated control group event rate of 0.60 and a relative risk
difference of 30 %, given α = 0.05 and β = 0.20) [12].
GRADE tables were created using standard GRADE
formats and procedures (with GRADEpro [13]). Meta-
analysis was performed in accordance with GRADE
methodology: summary odds ratios (sORs) and 95 %
confidence intervals were calculated when the outcomes
were considered relatively homogeneous regarding the
intervention and the population. This was done using
a random effects model with the “MAInput Table”
and “MAPooledEffect” functions from the MetaXL 2.1
add-in in Excel. No quality index was used. The sORs
and a measure for heterogeneity (I2) are shown in a
forest plot [14].
Results
Results of the review process
Results are reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement. A flowchart showing the number
of articles identified for all review questions during the
selection process is presented in in the Additional files
(see Additional file 2).
Overall, 62 articles were found for review question 2,
including 27 prospective studies and 35 retrospective
studies (see Additional file 3). Twelve articles provided
information on determinants of initiation, eight on
determinants of adherence, and 51 on determinants of
completion. Twenty-three articles were found for re-
view question 3, including twenty prospective and three
retrospective studies (see Additional file 4). Among the
prospective studies, seven articles described interven-
tions with short treatment regimens, four with DOT,
four with incentives, eight with social interventions,
and one described another type of intervention. Four
prospective studies provided data for more than one
outcome [15–21].
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Determinants of LTBI treatment initiation, adherence and
completion
Most determinants of LTBI treatment initiation, adher-
ence, and completion are from studies in the general
population, i.e. primarily unselected patients with LTBI
at clinics (Table 1). The most frequently reported deter-
minant associated with LTBI treatment uptake in the
general population was age, though the direction of the
effect was inconsistent. Most determinants related to
LTBI treatment completion.
With regards to LTBI treatment initiation, two studies
found healthcare workers (vs. non healthcare workers) to
be less likely to initiate treatment [22, 23] (no study found
a positive association); three studies found case contacts
(vs. no case contacts) [22–24], and two studies found im-
migrants or refugees (vs. born in country of study) [25, 26]
to be more likely to initiate LTBI treatment (no study
found an inverse association). With regards to LTBI treat-
ment completion, five studies found a positive association
between completion and immigrant or refugee status (vs.
born in country of study) [27–31], whereas two studies
found an inverse association [32, 33]. Two studies each
found that currently homeless individuals [30, 32] (vs. not
currently homeless) and people who injected drugs
(PWID) [23, 34] (vs. people who do not inject drugs) were
less likely to complete treatment (no study found a positive
association). Throughout the populations, unfavourable
social risk factors were associated with worse completion
[23, 25, 27, 35–38] (no study found a positive association).
Determinants of treatment initiation, adherence or comple-
tion within specific source populations with LTBI are pre-
sented in the Additional files (see Additional file 3), and
showed large analogy with the determinants identified for
the general population. Short (vs. long) treatment regimens
and treatments with DOT (vs. self-administered therapy
(SAT)) were found to be completed more often in the
general population with LTBI in six [31, 39–43] and three
[31, 44, 45] studies, respectively, (no study found an inverse
association). Adverse events were inversely associated with
completion in seven studies [30, 33, 41, 46–49] (no study
found a positive association). Similar results were found for
determinants of completion in individuals from the differ-
ent populations (see Additional file 3). Females [30, 44] (vs.
males) were more likely to complete treatment (no study
found men were more likely to complete treatment). Add-
itionally, alcohol use (vs. no alcohol use) was inversely as-
sociated with completion in four studies [29, 30, 32, 49]
(no study found a positive association).
Interventions to improve LTBI treatment initiation,
adherence and completion
Twenty prospective studies on interventions to im-
prove LTBI treatment initiation, adherence, and/or
completion provided evidence for the following questions
(Tables 2, 3, 4, 5, 6):
Does short LTBI treatment result in higher initiation,
adherence, or completion rates than long LTBI treatment
in individuals eligible for LTBI treatment (Table 2)?
Case contacts showed better adherence when receiving
short treatment (2 studies; sOR = 1.5; 95 % CI 1.0-2.3;
low heterogeneity, moderate quality of evidence) [21, 50]
(Fig. 1). One of these studies also provided completion
rates but found no association with shorter treatment
duration (OR = 0.8; 95 % CI 0.5–1.3; moderate quality of
evidence) [21]. All other studies found higher comple-
tion rates in the short treatment group: in immigrants
with LTBI (1 study; OR = 2.5; 95 % CI 1.7–3.6; moderate
quality of evidence) [38], in the general population with
LTBI (2 studies; sOR = 1.9; 95 % CI 1.1–3.5; large hetero-
geneity, moderate quality of evidence) [51–53] (Fig. 2),
and in case contacts (1 study; OR = 2.1; 95 % CI 1.9–2.3;
low quality of evidence) [20]. The latter result is con-
founded, however, by the use of DOT in the short treat-
ment group and SAT in the long treatment group.
Does DOT result in higher initiation, adherence, or
completion rates than SAT in individuals eligible for
LTBI treatment (Table 3)?
In undocumented migrants, significantly lower comple-
tion rates were found among those receiving twice weekly
clinic-based DOT compared to daily SAT (OR = 0.1; 95 %
CI 0.0–0.3; low quality of evidence) [54] or twice weekly
SAT (OR = 0.2; 95 % CI 0.1–0.6). In one other study, in
PWID, no effect of DOT administered by an outreach
nurse on completion rates of LTBI treatment was found
(OR = 1.1; 95 % CI 0.5–2.1; moderate quality of evidence).
However, when looking at the proportion of people who
took all doses, the DOT group performed significantly
better (OR = 31.5; 95 % CI 14.1–70.6) [17].
Two more studies compared DOT to SAT, but were
confounded: among case contacts with LTBI a shorter
treatment regimen was given in the DOT than in the SAT
group [20], and among PWID with LTBI the DOT group
received methadone treatment whereas the SAT group did
not [16]. Higher completion rates were found in the DOT
group among both case contacts (OR = 2.1; 95 % CI 1.9–
2.3; low quality of evidence) and PWID (OR = 14.5; 95 %
CI 5.1–42; very low quality of evidence).
Does treatment supported by (monetary) incentives result
in higher initiation, adherence, or completion rates than
treatment not supported by incentives in individuals eligible
for LTBI treatment (Table 4)?
Two studies in PWID with LTBI found higher comple-
tion rates for LTBI treatment among those who received
either a monetary incentive (adjusted OR [aOR] = 32.0;
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Table 1 Overview of determinants of LTBI treatment initiation, adherence and completion in the general population diagnosed
with LTBI
Determinant Specification determinant (vs. reference group) Number of articles
Positive association Inverse association
P R P R
Determinants of LTBI treatment initiation
Age Older age (vs. younger age) – 1 [49] – 2 [22, 26]





Refugee/immigrants (vs. born in country
of study)
1 [25] 1 [26] – –
Immigrants born in WHO category 3 or
5 country (vs. category 1 country)A
1 [25] – – –
HCW (vs. no HCW) – – – 2 [22, 23]
Case contact (vs. no case contact) 1 [24] 2 [22, 23] – –
Education Lower education level (vs. n.r.) 1 [24] – – –
Behaviour Alcohol use reported at baseline (vs. no
alcohol use reported)
– – – 1 [49]
Other Continuity of primary care by consulting a
regular physician (vs. n.r.)
1 [24] – – –
Pregnant (vs. not pregnant) – – – 1 [47]
Prior incarceration (vs. n.r.) 1 [24] – – –
Fear of getting sick with TB without medicine
(vs. no fear of getting sick)
1 [24] – – –
Previous BCG vaccination (vs. n.r.) – – – 1 [22]
Abnormal CXR findings consistent with
previous TB (vs. n.r.)
– 1 [22] – –
A non-employment reason for screening (vs. n.r.) 1 [24] – – –
Determinants of LTBI treatment adherence
Age Older age (vs. younger age) – – 1 [75] –
Ethnicity BiculturalD (vs. Hispanic or non-Hispanic) 1 [75] – –
Education Higher grades in school (vs. lower grades) 1 [75] – – –
Behaviour Risk behaviours (vs. n.r.)E – – 2 [75, 76] –
Adverse events Some somatic complaints (vs. n.r.) – – 1 [76] –
Determinants of LTBI treatment completion
Age Older (vs. younger) 3 [43, 58]B, C 4 [29, 31, 42, 44]G 3 [25, 77, 78] 6 [23, 28, 30, 41,
46, 79]
Gender Male (vs. female) – – – 2 [30, 44]
Ethnicity Hispanic/Latino ethnicity (vs. Asian ethnicity) – – 1 [78]
White Hispanic (vs. black, non-Hispanic) – 1 [30, 34, 46] – –
Country of birth (i.e. Haiti, Dominican Republic,




Asian/Pacific Islander (vs. white) – 2 [42, 44] – –
Region of origin (i.e. Latin America and Caribbean
or Asia and other) (vs. USA, Canada, Europe)
– 1 [41] – –
Black race (vs. n.r.) – – – 1 [29]G
Ethnicity (i.e. Asian, Non-Hispanic black or
Hispanic (vs. non-Hispanic white)
1 [31]
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HCW (vs. no HCW) – – – 1 [23]
Case contact (vs. no case contact) – 1 [31] – 1 [29]F
Currently homeless (vs. not currently homeless) – – – 2 [30, 32]
PWID (vs. no PWID) – – – 2 [23, 34]
Refugees/immigrants (vs. born in country of study) 1 [27] 4 [28–31]G 2 [32] [33]
Indication for LTBI treatment immunosuppression
(vs. case contact)
1 [43]C – – –
Health History of hepatitis A, B or C (vs. no history of
liver disease)
1 [77] – – –
Other medications reported at baseline
(vs. none reported)
– – – 1 [29]F
Use of concomitant medications by women
(vs. no use of concomitant medication)
– – – 1 [49]
Behaviour (Excess) alcohol use (vs. no alcohol use) – – – 4 [29, 30, 32, 49]F
Smoking (vs. non-smoking) 1 [43]C – – –
Treatment Treatment without H (vs. treatment with H) 1 [43]C 5 [31, 39–42] – –
9-months H (vs. other regimens) – – – 1 [23]
Regimen choice offered (vs. no regimen
choice offered)
– 1 [79] – –
Twice weekly RZ (vs. daily RZ) – 1 [81] – –
DOT (vs. SAT) – 3 [31, 44, 45] – –
Adverse events Adverse events (vs. no adverse events) – – – 7 [30, 33, 41,
46–49]
Adverse events (i.e. grade 1 or 2 hepatotoxicity,
grade 3 or 4 hepatotoxicity or adverse events




Other Not having been incarcerated within 6 months
of diagnosis (vs. n.r.)
1 [25] – – –
Referral reason (i.e. correctional/rehabilitation or
postpartum women) (vs. TST positive from screening)
– – – 1 [28]
Risk group (i.e. contact, medical riskH, population
riskI) (vs. low riskJ)
– 1 [31] – –
Cause of screening/referral (i.e. asylum seekers
or contacts) (vs. anti-TNF-α candidates)
– – – 1 [82]
Fear for venepuncture (vs. n.r.) – – 1 [83] –
Low TB risk perception (vs. n.r.) – – 1 [83] –
Plan to tell friends or family about LTBI
diagnosis (vs. n.r.)
1 [24] – – –
Home situation (i.e. child living with no or one
natural parent) (vs. living with both natural parents)
– – 1 [27] –
Spanish language (vs. non-Spanish language) – 1 [60] – –
Resident in a congregate setting (vs. never
or unknown)
– – – 1 [23]
Missed appointment call or letter (vs. no missed
appointment call)
– – – 1 [60]
No medical insurance (vs. medical insurance) – – – 1 [47]
Clinic attendance before treatment (vs. clinic
non-attendance before treatment)
– 1 [79] – –
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95 % CI 7.1–145; moderate quality of evidence) [55] or
methadone treatment (OR = 14.5; 95 % CI 5.0–42; very
low quality of evidence) [16] compared to those who
received no incentive. The results from the methadone
treatment study were confounded, however, by the use of
DOT in the methadone treatment group and SAT in the
control group. The provision of food or transportation
vouchers to released inmates with LTBI if they attended a
TB clinic upon release (OR = 1.1; 95 % CI 0.5–2.4; moder-
ate quality of evidence) [15] did not lead to better comple-
tion rates. In another study, no difference was found
between the provision of cash-incentives versus non-cash-
incentives to homeless individuals with LTBI (OR = 1.7;
95 % CI 0.7–4.3; low quality of evidence) [56].
Do social interventions result in higher initiation,
adherence, or completion rates than standard care in
individuals eligible for LTBI treatment (Table 5)?
Adherence coaching among the general population with
LTBI at clinics (low quality of evidence) and a cultural
intervention among immigrants (very low quality of
evidence) resulted in better adherence [19, 57]. Social
interventions were found to improve completion rates of
LTBI treatment compared to the standard care group in
all but one study, which provided peer-support among
PWID with LTBI (OR = 1.0; 95 % CI 0.7–1.5; high qual-
ity of evidence) and found no effect on completion [17].
Counselling and contingency contracting, adherence
coaching and self-esteem counselling, and peer-based in-
terventions in the general population showed better
completion rates (sOR = 1.4; 95 % CI 1.1–19; low hetero-
geneity, high quality of evidence) [19, 27, 58] (Fig. 3).
Education among inmates (OR = 2.2; 95 % CI 1.0–4.7;
moderate quality of evidence) [15], nurse case management
among homeless individuals (aOR = 3.0; 95 % CI 2.2–4.2;
high quality of evidence) [35], and case management with
attention for the cultural background of each individual
among immigrants (aOR = 7.8; 95 % CI 5.7–10.7; low
quality of evidence) [18] improved completion. The latter
study also found that this intervention led to higher initi-
ation rates (OR = 2.7; 95 % CI 1.9–3.8; low quality of
evidence).
Do interventions other than short treatment, directly
observed therapy, incentives or social interventions result
in higher initiation, adherence, or completion rates than
standard care in individuals eligible for LTBI treatment
(Table 6)?
One study showed that the use of IGRAs rather than TSTs
for diagnosis of LTBI improved the initiation rate of LTBI
treatment in healthcare workers with LTBI (OR = 8.8;
95 % CI 3.1–23; very low quality of evidence) [59].
Three retrospective studies performed in the general
population with LTBI showed significantly higher com-
pletion rates in the groups that received DOT, behaviour
modification techniques in combination with incentives,
or home to clinic follow-up, respectively [28, 44, 60] (see
Additional file 4).
Discussion
To the best of our knowledge, this is the first review to
systematically and comprehensively summarise data on
any determinant of, and intervention to improve, LTBI
treatment initiation, adherence and completion in all
types of populations.
Determinants
The most frequently found determinants of treatment
completion in our review were patient-related (i.e. type of
population with LTBI, demographic factors, drug/alcohol
abuse), therapy-related (e.g. short therapy regimens,
DOT, occurrence of adverse events), and socio-
economic (e.g. unemployment, lack of social support).
Unfavourable socio-economic factors were consistently
associated with poor completion of LTBI therapy.
These results should be interpreted with care, since
Table 1 Overview of determinants of LTBI treatment initiation, adherence and completion in the general population diagnosed
with LTBI (Continued)
Presumed non-recent TB infection (vs. presumed
recent TB infection)
– – – 1 [34]
Public health nurse referral (vs. no public health
nurse referral)
– – – 1 [60]
BCG Bacillus Calmette-Guérin; CXR chest radiograph; DOT directly observed therapy; H isoniazid; HCW healthcare worker; HK Hong Kong; i.e. id est; LTBI latent
tuberculosis infection; n.r. not reported; PWID people who inject drug; RZ rifampicin and pyrazinamide; SAT self-administered therapy; TB tuberculosis; TNF
tumor necrosis factor; TST tuberculin skin test; USA United States of America; WHO World Health Organisation
AWHO defined 5 categories of TB prevalence based on 1st (least prevalent) to 5th (most prevalent). BData analysed in individuals that underwent three
QFT-GIT. CData analysed in individuals who underwent at least one serial QFT-GIT. DBicultural is defined by questions separated into the domains Hispanic and
non-Hispanic, considering language use, linguistic proficiency and electronic media use. Individuals scoring high in both domains are considered bicultural.
ERisk behaviours: ever used alcohol, cigarettes, marijuana, been expelled or suspended from school, or been in a physical fight. FData analysed in Hispanic subjects for
one study. GData analysed in non-Hispanic subjects for one study HPersons with medical risk factors such as having a TST conversion within two years of a
negative TST, HIV infection, untreated or partially treated prior TB, suspected TB with an abnormal chest radiograph, being younger than five years of
age with a positive TST, or having a clinical condition associated with an increased risk of TB disease. Ipersons with population risk factors such as: recent immigrants to
the USA (5 years) from countries with high TB prevalence, homeless persons, residents and employees of congregate settings such as prisons and jails, and healthcare
facilities. Jpersons with low risk for developing TB disease (no case contact, no medical risk, no population risk factors)
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Table 2 Grading of the body of evidence for effectiveness of short versus long LTBI treatment. Question: Does short LTBI treatment result in higher initiation, adherence, or
completion rates than long LTBI treatment in individuals eligible for LTBI treatment?





Risk of bias Inconsistency Indirectness Imprecision Other considerations Short LTBI
treatment
OR (95 % CI)b Absolute
(per 1000
(95 % CI))cLong LTBI
treatment
Initiation
0 (0) No evidence
available
– – – – – – – – – – Critical
Adherence
2 (822) [21, 50] RCT Case contacts Seriousd Not serious Not serious Not serious None 344/391 = 88 %
(range: 82–92 %)
1.5 (1.0–2.3) 55 (4–92) ⊕⊕⊕O
Moderate
Critical
3HR or 2RZ vs.
6H or 9H
353/431 = 82 %
(range:7–86 %)
Completion
1 (352) [21] RCT Case contacts Seriouse Not serious Not serious Not serious None 106/153 = 69 % 0.8 (0.5–1.3) −46 (−156-49) ⊕⊕⊕O
Moderate
Critical
2RZ vs. 6H 145/199 = 73 %
1 (7731) [20] RCT Case contacts Very seriousf Not serious Not serious Not serious None 3273/3986 = 82 % 2.1 (1.9–2.3) 134 (119–146) ⊕⊕OO
Low
Critical
3H + RPT + DOT
vs. 9H + SAT
2585/3745 = 69 %
1 (590) [38] RCT Immigrants Seriousg Not serious Not serious Not serious None 213/296 = 72 % 2.5 (1.7–3.6) 206 (125–273) ⊕⊕⊕O
Moderate
Critical
3HR vs. 6H 154/294 = 52 %
3 (1552) [51–53] RCT General
population
Serioush Not serious Not serious Not serious None 568/785 = 72 %
(range: 61–91 %)
1.9 (1.1–3.5) 141 (23–241) ⊕⊕⊕O
Moderate
Critical
2RZ or 4R vs.
6H or 9H
459/767 = 60 %
(range: 57–76 %)
Bibliography: Spyridis et al. 2007 [50]; Tortajada et al. 2005 [21]; Sterling et al. 2011 [20]; Jimenez-Fuentes et al. 2013 [38]; Menzies et al. 2008 [53]; Menzies et al. 2004 [52]; Jasmer et al. 2002 [51]
n/N No of individuals with LTBI who initiated, or adhered to or completed treatment/total number of subjects; CI confidence interval; DOT directly observed therapy; 3H, 6H, 9H 3, 6 or 9 months isoniazid; 3HR
3 months isoniazid + rifampicin; OR odds ratio; 4R four months rifampin; RCT randomised controlled trial; RPT rifapentine; 2RZ 2 months rifampicin + pyrazinamide; SAT self-administered therapy
aIf >1 articles, weighed pooled point estimates and 95 % CI were calculated
bIf >1 articles, weighed pooled estimates and 95 % CI were calculated using a random effects model (without quality index)
cCalculated via GradePro
dSpyridis et al. 2007 [50]: no blinding. Tortajada et al. 2005 [21]: no blinding; use of unvalidated patient-reported outcomes (pill count and calendar annotations); early termination (due to higher toxicity in 2RZ arm,
unplanned interim analysis); dissimilarities between treatment arms (more foreign-born in 2RZ); unequal number of patients in the two groups
eTortajada et al. 2005 [21]: no blinding; use of unvalidated patient-reported outcomes (pill count and calendar annotations); early termination (due to higher toxicity in 2RZ arm, unplanned interim analysis); dissimilarities
in treatment groups (more foreign-born in 2RZ); unequal number of patients in the two groups
fSterling et al. 2011 [20]: unclear allocation concealment; no blinding; use of unvalidated patient-reported outcomes (pill count and self-report); dissimilarities between treatment arms (with respect to North American
Indians, subjects enrolled in a cluster, homelessness); exposure bias (DOT only in short treatment arm)
gJimenez-Fuentes et al. 2013 [38]: unclear allocation concealment; no blinding; dissimilarities between treatment arms (with respect to sex and undocumented migration status)
hMenzies et al. 2004 [52]: unclear allocation concealment; no blinding. Menzies et al. 2008 [53]: unclear allocation concealment; no blinding; early termination (due to lower toxicity in 4R arm, planned interim analysis).
Jasmer et al. 2002 [51]: lack of allocation concealment (alternate weeks); inadequate sequence generation (alternate weeks); no blinding; unclear treatment adherence assessment; dissimilarities between treatment














Table 3 Grading of the body of evidence for effectiveness of DOT versus SAT. Question: Does DOT result in higher initiation, adherence, or completion rates than SAT in
individuals eligible for LTBI treatment?






Risk of bias Inconsistency Indirectness Imprecision Other
considerations
DOT OR (95 % CI) Absolutea (per
1000 (95 % CI))SAT
Initiation
0 (0) No evidence
available
– – – – – – – – – – Critical
Adherence
0 (0) No evidence
available
– – – – – – – – – – Critical
Completion





79/100 = 79 %






5/39 = 13 %
1 (7731) [20] RCT Case contacts Very seriousg Not serious Not serious Not serious None 3273/3986 = 82 % 2.1 (1.9–2.3) 134 (119–146) ⊕⊕OO
Low
Critical
DOT + 3H + RPT
vs. SAT + long H
2585/3745 = 69 %





22/53 = 41 %
Bibliography: Chaisson et al. 2001 [17]; Batki et al. 2002 [16]; Sterling et al. 2011 [20]; Matteelli et al. 2000 [54]
n/N No of individuals with LTBI who initiated, or adhered to or completed treatment/total number of subjects; CI confidence interval; DOT directly observed therapy; H, 3H (3 months) isoniazid; OR odds ratio; PWID
people who inject drugs; RCT randomized controlled trial; RPT rifapentine; SAT self-administered therapy
aCalculated via GradePro
bBoth studies with PWID population are presented separately, since one of the studies applies DOT + an incentive as intervention
cChaisson et al. 2001 [17]: unclear allocation concealment; no blinding; use of unvalidated patient-reported outcomes in SAT arm (self-report; urine tests and MEMS in a subset of patients in this study show that
self-reported adherence was greatly overestimated, thereby possibly underestimating the effect of DOT)
dBatki et al. 2002 [16]: no blinding; use of unvalidated patient-reported outcomes in SAT arm (monthly medication pick-up); dissimilarities between treatment arms (age, Addiction Severity Index psychiatric and Beck
depression inventory); exposure bias (incentive in DOT arm)
etotal number of events <125
fApproximately half of the intervention group (37/72) also received substance abuse counselling
gSterling et al. 2011 [20]: unclear allocation concealment; no blinding; use of unvalidated patient-reported outcomes in SAT arm (pill count and self-report); dissimilarities between treatment arms (with respect to North
American Indians, subjects enrolled in a cluster, homelessness); exposure bias (short treatment in DOT arm)
hMatteelli et al. 2000 [54]: unclear allocation concealment; no blinding; very large loss to follow-up; unclear treatment adherence assessment in SAT arm; unequal numbers in treatment arms; early termination (due to
low completion rates in DOT arm). Early termination partially accounts for the low numbers in this study, and as we already downgraded for this (serious imprecision), we decided not to downgrade for it again in the
risk of bias














Table 4 Grading of the body of evidence for the effectiveness of (monetary) incentives. Question: Does treatment supported by (monetary) incentives result in higher initiation,
adherence, or completion rates than treatment not supported by incentives in individuals eligible for LTBI treatment?
Quality assessment n/N = % Effect Quality Importance
No of studies
(No of participants)
Design Population - treatment-
intervention
Risk of bias Inconsistency Indirectness Imprecision Other
considerations





0 (0) No evidence
available
– – – – – – – – – – Critical
Adherence
0 (0) No evidence
available
– – – – – – – – – – Critical
Completion




+DOT vs. no incentive
+ SATe
5/39 = 13 %





2/55 = 3.6 %





12/103 = 12 %
1 (119) [56] RCT Homeless - long H or
short HR





44/57 = 77 %
Bibliography: Tulsky et al. 2004 [56]; Batki et al. 2002 [16]; Malotte et al. 2001 [55]; White et al. 2002 [15]
n/N: No of individuals with LTBI who initiated, or adhered to or completed treatment/total number of subjects; CI: confidence interval; DOT: directly observed therapy; H: isoniazid; HR: isoniazid and rifampicin;
OR: odds ratio; PWID: people who inject drugs; RCT: randomised controlled trial
aCalculated via GradePro
bBoth studies with PWID population are presented separately, since one of the studies applies incentive + DOT as intervention
cMalotte et al. 2001 [55]: unclear sequence generation; partly blinded
dBatki et al. 2002 [16]: no blinding; use of unvalidated patient-reported outcomes in SAT arm (monthly medication pick-up); dissimilarities between treatment arms (age, Addiction Severity Index psychiatric and Beck
depression inventory); exposure bias (DOT in incentive arm)
eApproximately half of the intervention group (37/72) also received substance abuse counselling
fWhite et al. 2002 [15]: partly blinded
gAdjusted OR, adjusted for: treatment condition, recruitment status, binge drinking
hInmates who started treatment in jail and were released before treatment completion
iTulsky et al. 2004 [56]: partly blinded; dissimilarities between treatment arms (primary housing in last year shelter/street; not found to be an independent predictor of completion in this study)this study presents data
for incentive vs. another incentive (rather than vs. no incentive)
jAdjusted OR, not reported which factors this OR was adjusted for
k$25 equivalent in food or transportation vouchers
lTotal number of events <125
mPatients with normal chest X-rays prescribed H, while those with evidence of old TB on chest X-ray were prescribed HR. Participants randomly assigned to the cash or non-cash incentive. Non-cash incentives














Table 5 Grading of body of evidence for the effectiveness of social interventions. Question: Do social interventions result in higher initiation, adherence, or completion rates
than usual care in individuals eligible for LTBI treatment?









OR (95 % CI)c Absoluted
(per 1000
(95 % CI))No social
intervention
Initiation
1 (946) [18] Observational
study
Immigrants Not seriouse Not serious Not serious Not serious None 389/442 = 88 % 2.7 (1.9–3.8) 149 (107–181) ⊕⊕OO
Low
Critical












1 (184) [57] Observational
study











Not seriousj Not serious Not serious Not serious None 331/515 = 64 %
(range: 46–84 %)






counselling & peer based
253/413 = 61 %
(range: 38–76 %)
1 (946) [18] Observational
study






205/557 = 37 %
1 (216) [15] RCT Inmatesk Not seriousl Not serious Not serious Seriousm None 24/106 = 23 % 2.2 (1.0–4.7)n 108 (4–267) ⊕⊕O
Moderate
Critical
Education 12/103 = 12 %
1 (520) [35] RCT Homeless Not seriouso Not serious Not serious Not serious None 173/279 = 62 % 3.0 (2.2–4.2)p 268 (189–339) ⊕⊕⊕⊕
High
Critical














Table 5 Grading of body of evidence for the effectiveness of social interventions. Question: Do social interventions result in higher initiation, adherence, or completion rates
than usual care in individuals eligible for LTBI treatment? (Continued)
1 (199) [17] RCT PWID Not seriousq Not serious Not serious Not serious None 79/101 = 78 % 1.0 (0.7–1.5) 2 (−75-62) ⊕⊕⊕⊕
High
Critical
Peer support vs. no peer
support
79/100 = 79 %
Bibliography: Goldberg et al. 2004 [18]; Hovell et al. 2003 [19]; Ailinger et al. 2010 [57]; Kominski et al. 2007 [27]; Hirsch-Moverman et al. 2013 [58]; White et al. 2002 [15]; Nyamathi et al. 2006 [35]; Chaisson et al.
2001 [17]
n/N: No of individuals with LTBI who initiated, or adhered to or completed treatment/total number of subjects. CI: confidence interval; H: isoniazid; OR: odds ratio; RCT: randomized controlled trial
aIf >1 articles, weighed pooled point estimates and 95 % CI were calculated
bAll groups H > 4 months
cIf >1 articles, pooled estimates and 95%CI were calculated using a random effects model (without quality index)
dCalculated via GradePro
eGoldberg et al. 2004 [18]: use of unvalidated patient-reported outcomes (self-report); proportion of children aged 5-14 years was higher during one period than the other (19 % vs. 13 %, p = 0.003)
fNo adherence rates were provided as outcome; instead, the cumulative mean number of pills taken per group was presented
gHovell et al. 2003 [19]: unclear allocation concealment; unclear sequence generation; partly blinded. Not downgraded for these risk of bias aspects because already downgraded for imprecision
hTotal sample size <230
iAilinger et al. 2010 [57]: use of unvalidated patient-reported outcomes (self-report) convenience sample
jHovell et al. 2003 [19]: unclear allocation concealment; unclear sequence generation; partly blinded. Kominski et al. 2007: unclear allocation concealment; no blinding; unclear if intention-to-treat analysis
was performed; use of unvalidated patient-reported outcomes (self-report). Hirsch-Moverman et al. 2013: unclear allocation concealment; unclear sequence generation; partly blinded; use of unvalidated
patient-reported outcomes (self-report)
kInmates who started treatment in jail and were released before treatment completion
lWhite et al. 2002 [15]: partly blinded
mTotal number of events <125
nAdjusted OR, not reported which factors this OR was adjusted for
oNyamathi et al. 2006 [35]: unclear allocation concealment; unclear sequence generation; partly blinded; dissimilarities between treatment arms (daily alcohol or drug use [significantly associated with non-completion
in this study]; male, recruitment site [both not significantly associated with completion in this study], lifetime intravenous drug use, recent self-help program)
pAdjusted OR, adjusted for: age, sex, high-school graduate, never married, medical insurance, recruited from homeless shelter, years homeless, treatment completion important, intended to adhere, daily alcohol/drug
use, recent self-help program, emotional well-being, social support, recent hospitalization, recent victimization
qChaisson et al. 2001 [17]: unclear allocation concealment; no blinding; use of unvalidated patient-reported outcomes (self-report; urine tests and MEMS in a subset of patients in this study show that














Table 6 Grading of body of evidence for effectiveness of other interventions. Question: Do interventions (other than short treatment, incentives or social intervention) result in
higher initiation, adherence, or completion rates than usual care in individuals eligible for LTBI treatment?















Not seriousb Not serious Not serious Seriousc 32/62 = 52 % 8.8 (3.1–23) 413 (168–631) ⊕OOO
Very low
Critical
Use of IGRAs 5/45 = 11 %
Adherence
0 (0) No evidence
available
– – – – – – – – – – Critical
Completion
0 (0) No evidence
available
– – – – – – – – – – Critical
Bibliography: Sahni et al. 2009 [59]
n/N No of individuals with LTBI who initiated, or adhered to or completed treatment/total number of subjects; CI confidence interval; IGRAs Interferon Gamma Release Assay; OR odds ratio; PWID people who inject
drugs; RCT randomised controlled trial
aCalculated via GradePro
bUse of unvalidated patient-reported outcomes (telephone interview)














different measures of associations were used in the studies,
the reference groups varied between studies, and data on
non-significant factors were not always quantified in the
studies and were therefore not listed in this review. How-
ever, the same socio-economic factors were also predictors
of non-adherence to highly active antiretroviral therapy in
human immunodeficiency virus (HIV)-patients or to car-
diovascular medication [61–65]. Also, adverse events have
been associated with worse adherence to treatment for all
these conditions [61, 62]. Similar factors were associated
with adherence to treatment for active TB [61].
Interventions
Initiation
Some evidence was found that the use of IGRAs rather
than TSTs [59], or a social intervention using case
management with attention to an individual’s cultural
background might positively influence the initiation
rate of LTBI treatment [18].
Adherence
Our meta-analysis showed that case contacts had better ad-
herence if they received short treatment compared to those
on long treatment regimens [21, 50]. Social interventions
in the form of adherence coaching of adolescents with
LTBI and cultural interventions among immigrants with
LTBI also resulted in improved adherence [19, 57].
Completion
Overall, completion rates of LTBI treatment were better
among groups receiving shorter regimens than those with
longer treatment regimens. The only outcome regarding
the effect of shorter treatment on completion rates for
which no effect was found could be explained by a rela-
tively high rate of hepatotoxicity (11 %) found in the short
treatment arm compared to the long treatment arm (3 %)
[21]. This led to premature termination of the study. The
applied short regimen of rifampicin plus pyrazinamide is
currently not generally offered to persons with LTBI due
to its association with hepatotoxicity [66].
Mixed results were found on the effect of DOT on com-
pletion rates of LTBI treatment. The significantly lower
completion rates among those receiving clinic-based DOT
in one study might be attributable to the difficulty un-
documented migrants have in reporting regularly to health
services to collect their drugs [54]. The study in which no
effect was found among PWID did find that more people
in the DOT group took all doses and, importantly, also
contacts with LTBI (random effects model) 





Q=0.61; p=0.43; I2 %0=
Study Adherence – short vs. long treatment in case 
0 1 2 3 4
OR
Fig. 1 Forest plot for adherence to short vs. long LTBI treatment in case contacts with LTBI
Study Completion – short vs. long treatment in the general








Q=10.94; p=0.004; I2 %28=
0 1 2 3 4 5 6 7 8 9 10 11
OR
Fig. 2 Forest plot for completion of short vs. long LTBI treatment in the general population diagnosed with LTBI
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found that the number of self-reported doses taken was
likely to be greatly over-estimated [17]. With regards to
two other types of long-term treatment, highly active anti-
retroviral therapy in HIV-patients and TB treatment, no
overall benefit of DOT compared to SAT was found on
viral load among HIV-patients or cure among TB patients
in reviews by Nachega et al. and Volmink et al. [67, 68].
Of the studies reporting on the effect of incentives, two
studies conducted in PWID with LTBI found a positive re-
sult (one of which was confounded), and the other study in
released inmates found no effect. The success of incentives
is likely to be both population and setting dependent. Lutge
et al. reviewed the literature on material incentives and
treatment for latent TB or active TB disease and concluded
that the effect on long-term adherence and completion is
not clear [69].
Social interventions to improve LTBI treatment uptake
included case management with attention for an individ-
ual’s cultural background, adherence coaching, counselling,
contingency contracting, education, nurse case manage-
ment and peer-based interventions. Most studies on this
topic showed better completion rates in the intervention
group than in the standard-care group, regardless of the
type of social intervention. In a review of RCTs, Schroeder
et al. found patient education to be largely unsuccessful in
improving adherence to blood pressure-lowering medica-
tion, whereas some motivational strategies and complex
interventions were successful [70]. In three out of the
seven RCTs in a review of Schedlbauer et al. social inter-
ventions (i.e. patient information and education, intensified
patient care, or a complex behavioral approach) improved
adherence rates to lipid-lowering medication) [71].
Other reviews
Several other reviews present data on interventions to im-
prove medication uptake among LTBI patients. These re-
views had specific questions, for example the effect of lay
healthcare workers on completion of LTBI treatment [72],
interventions to improve the health of the homeless [73],
education or counselling to improve completion of LTBI
treatment [7], effects of rifampicin monotherapy or
rifamycin-combination therapy versus isoniazid for prevent-
ing active TB and the role of completion rates [9]; incen-
tives to reinforce medication adherence, including for LTBI
treatment [10, 69]. However, these reviews included only a
small number of studies with the specific aim to investigate
interventions to improve LTBI treatment initiation, adher-
ence or completion. Some of these articles were also in-
cluded in the current review; some could not be included
in our review because we used different inclusion criteria.
Limitations
The definitions of completion varied between the included
studies, as did the ways in which treatment adherence was
assessed and in which completion rates were calculated.
For example definitions used varied from “completed four
months of rifampicin” to “picked up nine months of
isoniazid within twelve months” and “took at least 80 % of
the prescribed medication within twenty weeks”. This
heterogeneity complicates comparison of rates between
studies and hampers meta-analysis and interpretation of
the results. Since adherence and completion are similar
concepts in the sense that full adherence to a treatment
regimen leads to its completion, the limitations that are
applicable to measures for completion are also applicable
to adherence.
There is no standard definition for LTBI using tuberculin
reactivity which is universally accepted.
There were no pre-set LTBI diagnostic criteria for in-
clusion of the studies in this review, the inclusion relied
on reporting of the diagnostic criteria of the individual
studies; if the study considered a case to be diagnosed
then the study was included in the review and those
cases were analysed.
Only determinants that showed a statistically significant
association with initiation, adherence and completion were
listed in this article, this should be taken into account
when interpreting the results. The power of a study to
Study Completion – social intervention vs. no intervention 
among general population diagnosed with LTBI
(random effects model) 




Summary estimate 1.41 (1.06-1.89) 100.00
Q=0.75; p=0.36; I2 %0=
0 1 2 3OR
Fig. 3 Forest plot for completion of LTBI treatment using social interventions in the general population diagnosed with LTBI
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detect a significant effect was not taken into account in this
review. Additionally, the determinants were merely de-
scribed and no summary analyses were done because the
non-significant determinants were not quantified and
because of heterogeneity between the included studies.
Comparison of studies is also complicated by the fact that
different measures of association were used by the included
studies; reference groups may differ; or the definition of
the determinant itself might vary. These intricacies would
be lost when grouping the determinants.
We calculated summary estimates for studies with simi-
lar populations and interventions. However, the studies
were still quite heterogeneous. Calculation of summary
estimates by combining studies without correcting for
possible bias-causing factors between studies may cause
bias in the results. Furthermore, the I2 estimates need to
be interpreted with caution because each meta-analysis
only included three studies.
Finally, when conducting a systematic review, any limita-
tions of included studies (e.g. lack of controlling for relevant
covariates) inherently become limitations of data presented
in the review.
Gaps and future research
The number of intervention studies in specific popula-
tions was scarce. In order to generate evidence on the
effectiveness of context-specific interventions to improve
the uptake of LTBI treatment, RCTs tailored to specific
populations, with consideration of available resources
and infrastructure of the health system, are necessary
[11]. Although clinically relevant, no determinants of ini-
tiation, adherence or completion were found for patients
with comorbidities.
Ultimately, the effect of LTBI treatment on the de-
velopment of TB disease is important, and initiation,
adherence and completion rates of LTBI treatment are
intermediate determinants. In a subgroup analysis of a
network meta-analysis of RCTs to determine the most
efficacious regimen for preventing active TB disease
[74], no evidence of a relationship between adherence
(expressed as overall percentage of doses received)
and efficacy was found. Still, more information on the
association between treatment adherence and efficacy
for prevention of active TB may be valuable.
Conclusions
Clinical benefit to individuals with LTBI and the success
of the LTBI control programme in general are dependent
on individuals taking the medication and completing the
full course of treatment [11]. In the first part of this review,
it was found that initiation and completion rates of LTBI
treatment were frequently suboptimal and varied greatly
within and across different populations. Taking determi-
nants of initiation, adherence, and completion into account
is an important first to step to plan interventions to
improve these rates.
The available evidence on the effect of interventions on
treatment initiation, adherence and completion presented
in this review suggests that some interventions, notably
the use of shorter treatment regimens and social interven-
tions, have a positive effect on adherence and completion.
Overall, however, the evidence was inconclusive and
recommendations on the best interventions to improve
uptake of LTBI medication are hampered by the hetero-
geneity of the studies. The benefit of interventions to
improve treatment completion, such as incentives and
DOT, appears to be population and setting dependent.
Specific needs of the different populations with LTBI
should be addressed taking into consideration the local
context, specific settings and conditions in which the
LTBI treatment programme is implemented.
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